Skip to main content

Twist Bioscience Corp

For the period ended Sep 30, 2024. Filed Nov 18, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Nov 18, 2024

TWST$135.34+12.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 15. Exhibits, financial statement schedules

Documents filed as part of this report are as follows:

(a)Consolidated Financial Statements

Our Consolidated Financial Statements are included in the “Index to Consolidated Financial Statements” under Part II, Item 8 and filed as part of this Annual Report on Form 10-K.

(b)Consolidated Financial Statement Schedules

All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto.

(c)Exhibits

Set forth below is a list of exhibits that are being filed or incorporated by reference into this Annual Report on Form 10-K:

ExhibitNumberDescriptionFiled /Furnished /Incorporatedby Referencefrom FormIncorporatedbyReferencefrom ExhibitNumberDate Filed
3.1Amended and Restated Certificate of Incorporation8-K3.111/7/2018
3.2Amended and Restated Bylaws8-K3.111/18/2022
4.1Form of common stock certificateS-1/A4.110/17/2018
4.2Description of Common Stock10-K4.511/20/2020
+10.12013 Stock Plan and forms of agreement thereunderS-110.110/3/2018
+10.22018 Equity Incentive Plan and forms of agreement thereunderS-1/A10.210/17/2018
+10.32018 Employee Stock Purchase PlanS-1/A10.310/17/2018
+10.4Executive Incentive Bonus PlanS-110.410/3/2018
+10.5Form of Indemnification Agreement between Twist Bioscience Corporation and each of its Officers and DirectorsS-1/A10.810/17/2018
+10.6Twist Bioscience Corporation Inducement Equity Incentive Plan and related forms of award agreements thereunderS-899.18/25/2023
10.7Lease Agreement by and between Twist Bioscience Corporation and ARE-San Francisco No. 32. LLC dated March 21, 2018S-110.1110/3/2018
10.7.1First Amendment to Lease by and between Twist Bioscience Corporation and ARE-San Francisco No. 32, LLC, dated March 21, 201910-Q10.25/1/2019
ExhibitNumberDescriptionFiled /Furnished /Incorporatedby Referencefrom FormIncorporatedbyReferencefrom ExhibitNumberDate Filed
10.8*Lease Agreement by and between Twist Bioscience Corporation and PWII Owner, LLC, dated December 18, 20208-K10.112/22/2020
10.8.1*First Amendment to Lease between Twist Bioscience Corporation and PWII Owner, LLC, dated April 13, 20218-K10.14/16/2021
10.9†End User Supply Agreement by and between Twist Bioscience Corporation and FUJIFILM Dimatix, Inc., dated November 5, 2015S-110.1410/3/2018
10.10Amended and Restated Employment Agreement dated October 26, 2022 between Twist Bioscience Corporation and Patrick Finn10-Q10.12/7/2023
10.1Employment Agreement dated December 18, 2023 between Twist Bioscience Corporation and Adam Laponis10-Q10.12/2/2024
10.1Amendment to Employment Agreement dated March 20, 2024 between Twist Bioscience Corporation and James Thorburn10-Q10.15/2/2024
10.1Consulting Agreement dated October 8, 2024 by and between Twist Bioscience Corporation and James ThorburnFiled herewith
10.14Amended and Restated Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and Emily LeproustFiled herewith
10.15Amended and Restated Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and James ThorburnFiled herewith
10.16Amended and Restated Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and Paula GreenFiled herewith
10.17Amended and Restated Employment Agreement dated September 9, 2022 between Twist Bioscience Corporation and William BanyaiFiled herewith
10.18Amended and Restated Employment Agreement dated September 2, 2024 between Twist Bioscience Corporation and Dennis ChoFiled herewith
ExhibitNumberDescriptionFiled /Furnished /Incorporatedby Referencefrom FormIncorporatedbyReferencefrom ExhibitNumberDate Filed
10.19Employment Agreement dated April 24, 2023 between Twist Bioscience Corporation and Robert WernerFiled herewith
19.1Insider Trading Compliance ProgramFiled herewith
21.1List of subsidiaries of the RegistrantFiled herewith
23.1Consent of Independent Registered Public Accounting FirmFiled herewith
31.1Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by President and Chief Executive OfficerFiled herewith
31.2Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Rule 13(a)-14(a)/15d-14(a), by Chief Financial OfficerFiled herewith
32.1Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by President and Chief Executive OfficerFurnishedherewith
32.2Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Financial OfficerFurnishedherewith
97.1Compensation Recovery PolicyFiled herewith
101.INSXBRL Instance DocumentFiled herewith
101.SCHXBRL Taxonomy Extension Schema DocumentFiled herewith
101.CALXBRL Taxonomy Extension Calculation Linkbase DocumentFiled herewith
101.DEFXBRL Taxonomy Extension Definition Linkbase DocumentFiled herewith
101.LABXBRL Taxonomy Extension Label Linkbase DocumentFiled herewith
ExhibitNumberDescriptionFiled /Furnished /Incorporatedby Referencefrom FormIncorporatedbyReferencefrom ExhibitNumberDate Filed
101.PREXBRL Taxonomy Extension Presentation Linkbase DocumentFiled herewith
104Cover page from the Company’s Annual Report on Form 10-K for the year ended September 30, 2024, formatted in Inline XBRL
  • Indicates a management contract or compensatory plan.
*Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.
†Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment that was separately filed with the SEC.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.